Dietrich A. Stephan, Ph.D.

Chairman & CEO, Founder

Dr. Stephan is an industry veteran having had a career in academia and in industry. Stephan served as Deputy Director for Discovery Research and chair of the neurogenomics division at TGen, and served as professor and chairman of the Department of Human Genetics at the University of Pittsburgh/UPMC. He has had academic affiliations with Harvard Medical School, Johns Hopkins University and Children's National Medical Center. Stephan has identified the molecular basis of dozens of rare and common diseases. Stephan has founded or co-founded 14 biotechnology companies to chaperone novel innovations to market with a focus on molecular diagnostics and first-in-class therapeutics. Stephan co-founded Navigenics, Inc. (a pioneer in direct-to consumer genomic testing), was founding Chairman of the Board of Pendulum, Inc. (microbiome modulating therapies), was an early advisor to Guardant Health, Inc. (liquid biopsy), is founding Chairman of the Board Peptilogics, Inc. (deep machine learning to develop peptide therapies), was part of the team that developed Genia Technology, Inc.'s single molecule electrical detection DNA sequencing platform acquired by Roche, and others. Stephan received his B.S. from Carnegie Mellon University, Ph.D. from the University of Pittsburgh and did his fellowship at NHGRI/NIH.

Todd P. Branning

Chief Financial Officer

Mr. Branning has more than 25 years of experience leading corporate finance and accounting, tax, financial planning and analysis, and investor relations for several publicly traded pharmaceutical companies. Prior to joining NeuBase, Mr. Branning was CFO of Phathom Pharmaceuticals, Inc., a publicly traded late clinical-stage biopharmaceutical company. Before that, he was Senior Vice President, CFO of Amneal Pharmaceuticals, Inc., a publicly traded pharmaceutical company, where he helped to build, leverage, and optimize infrastructure following the completion of a transformational merger. Prior to joining Amneal, he was Senior Vice President, CFO of the global generic medicines division at Teva Pharmaceutical Industries Ltd., a multinational generic pharmaceuticals company, where he led the finance function and served on the leadership team responsible for managing the day-to-day operations of Teva's largest multi-billion-dollar commercial unit. Mr. Branning has also held financial leadership roles at Allergan plc, PricewaterhouseCoopers LLP, PPG Industries, Inc., and Merck & Co., Inc. Mr. Branning received his BBA from the University of Miami and MBA from Carnegie Mellon University. Mr. Branning is also a Certified Public Accountant and has completed a CFO certification program at The Wharton School at the University of Pennsylvania.

Sandra Rojas-Caro, M.D.

Chief Medical Officer

Dr. Rojas-Caro has broad R&D leadership, executive management and team-building experience in private and public biotech companies and large pharma. She has been directly involved in successful global regulatory submissions, including an FDA and EMA approval and more than 10 investigational new drug (IND) applications. Most recently, she was Chief Medical Officer for Gemini Therapeutics, a company focused on redefining age-related macular degeneration (AMD) and linked disorders with precision medicine. At Gemini, she led development through several milestones, including the company’s first IND and the first cohorts of genetically selected patients dosed with the company’s leading biologic therapeutic. Prior to Gemini, Sandra served as Chief Medical Officer for Aeglea BioTherapeutics (Nasdaq: AGLE), a biotechnology company developing a new generation of enzyme-based therapeutics to treat inborn errors of metabolism (IEM). Prior to Aeglea, she served as Group Vice President of Clinical Research and Development at Synageva BioPharma where she was instrumental in leading the clinical development team that secured the U.S. and E.U. approval of Kanuma® (sebelipase alfa) for the treatment of lysosomal acid lipase deficiency, as well as advancing the clinical development of other IEM programs. Following the acquisition of Synageva by Alexion, Dr. Rojas-Caro served as Vice President and R&D Project Team Leader for the Metabolic Rare Diseases Unit, and she supported the post-merger integration. Earlier in her career, she held roles in clinical and translational research with increasing levels of responsibility at Roche, Array BioPharma and Pfizer, where she was responsible for the design and implementation of early development clinical strategy across a broad range of indications.

Anthony Rossomando, Ph.D.

Chief Technology Officer

Dr. Rossomando has more than 25 years of experience as a biopharmaceutical drug developer who has successfully led teams from start-up to global biotechnology companies that have established the upstream and downstream process development of biologics and peptide molecules, including RNAi/siRNA, to advance multiple programs into clinical trials and commercialization in several therapeutic areas of neuroscience, rare diseases, and oncology. At NeuBase, Dr. Rossomando will be responsible for manufacturing and process development, analytical development, and biophysical characterization in support of FDA regulatory submissions. Prior to joining NeuBase, Dr. Rossomando was Chief Process Development Officer at Pinetree Therapeutics, where he oversaw early-stage upstream and downstream process development for bi-specific antibodies for oncology. Previous to that, he held the following positions: Vice President of Technology Operations at Anokion; Senior Director of Analytical Development at Alexion Pharmaceuticals; Vice President, Early-Stage Development at Synageva BioPharma (acquired by Alexion), Senior Director siRNA Bioprocessing at Alnylam Pharmaceuticals; Principal Scientist and Director, Protein Sciences at Biogen; and Staff Scientist at Bayer Corporation. Dr. Rossomando earned a Ph.D. in microbiology at the University of Virginia, where he researched MAP kinase and MEK1 cell signaling with Drs. Michael Weber and Thomas Sturgill, and completed his postdoctoral training at Cold Spring Harbor Labs, where he studied the CDC2 kinase and MEK1 signaling pathways with Dr. Daniel Marshak.

William Mann, Ph.D.

Chief Operating Officer

Dr. William (Bill) Mann has more than 25 years of experience in the biopharma industry. Most recently, he served as the President, CEO, and Board member of Helsinn Therapeutics U.S., where he transformed the development-focused company into a profitable commercial entity with a portfolio that included Aloxi®, Akynzeo®, Halaven®, and Zykadia®. Prior to Helsinn, he was Vice President of Corporate Development at Sapphire Therapeutics, where he led several business development transactions, including the licensing of anamorelin to Ono Pharmaceutical Co, Ltd and played a key role in the sale of the company to Helsinn Healthcare SA. Also in this role, Bill managed the international Phase 2B study of anamorelin, which is now approved in Japan as Adlumiz® for the treatment of cancer cachexia. Bill began his professional career at Novartis, where he led a multidisciplinary drug discovery program and later served as Director of Business Development. He received bachelor and doctorate degrees in biochemistry from the University of Aberdeen, Scotland, completed postdoctoral studies at The Rockefeller University, and obtained an MBA from Rutgers University.

Shannon McCarthy

Chief People Officer

As Chief People Officer, Ms. McCarthy  is responsible for ensuring that our people, the foundation of the company, are given the framework and support within which to excel and be maximally effective. This includes building a thriving ecosystem of coaching and team development resources to create a healthy culture of authenticity, real-time unemotional team-based creative problem solving abilities, and effective communication skills. The result is an engaged and dynamic team fully aligned with our corporate objectives. The company believes caring for and investing in our people is critically necessary for ultra-peak performance and to ensure our team can outperform and maintain the growth trajectory of the business. Ms. McCarthy’s background is as a former corporate CEO, executive coach, strategic advisor, and leadership development consultant. She draws from her extensive studies in psychology, business strategies, systems thinking, and high-performance training to create a unique methodology which produces transformational results to enable leaders and teams to make vastly better decisions, faster. She has designed and facilitated programs on leadership, personal mastery, team learning, organizational effectiveness, and coaching for hundreds of executives and companies worldwide, including NASA, Google, Amazon, Facebook, Miraval, Wells Fargo, the Federal Reserve, Lawrence Livermore National Laboratory, Levi’s, The Gap, Bank of America, and Charles Schwab, among others.

Alan Scrivner, J.D.

VP, IP and Legal

Prior to NeuBase, Mr. Scrivner was a consultant for more than five years, providing clients support for patent and litigation strategy. Previous to that, he was Senior Patent Counsel from 2007-2009 and then Vice President, Therapeutic Area Patents from 2009-2015 at GlaxoSmithKline in Research Triangle Park. Prior to GSK, Mr. Scrivner held the following positions: Senior Director of Intellectual Property at Atherogenics; Patent Attorney at Bend Research; Associate General Counsel, Intellectual Property at Pharmacia Corporation (formerly Monsanto and Searle). Mr. Scrivner is registered to practice before the United States Patent & Trademark Office (USPTO).

Ron Sarkar, Ph.D., MBA

VP, Business Development

Before joining NeuBase, Dr. Sarkar served as business development and corporate strategy consultant for biotech companies with platform technologies for novel therapeutics. Most recently, he was Senior Director at Assembly Biosciences, a clinical stage biopharmaceutical company with therapeutic product candidates for the treatment of chronic hepatitis B virus (HBV) infection. Prior to that, Dr. Sarkar held positions of increasing responsibility at Allergan, and then post-acquisition, at Teva. In addition to his business development experience, he has contributed to various stages of development and commercialization of seven marketed therapeutic products. Dr. Sarkar received his MBA from The Wharton School of the University of Pennsylvania and his Ph.D. in pharmaceutics and drug delivery at University of Georgia.

Renta Hutabarat, Ph.D.

VP, ADME and Pharmacology

Dr. Hutabarat has more than 25 years of experience in drug metabolism and pharmacokinetics, toxicology, pharmacology, clinical pharmacology, bioanalytical, and biomarker development. She has a proven track record in the nonclinical/clinical drug development fields, including contributing to bringing siRNA molecules to approval and to patients. At Alnylam, she worked and contributed to the development of the lipid nanoparticle siRNA and GalNAc delivery and contributed to bringing Patisiran (ALN-TTR02) and ALN-VSP02 siRNA in lipid nanoparticles (LNP), and GalNac conjugated siRNA, Vultrisiran (ALN-TTRSC02), Lumisiran (ALN-GO1), Inclisiran (ALN-PCS02), Fitusiran (ALN-AT3SC) and Givosiran (ALN-AS1). In her career, she has held senior positions at Burroughs Wellcome/Glaxo-Wellcome, Genetics Institute/Wyeth, Regeneron, Purdue Pharma, Archemix, Alnylam, Vitrisa Therapeutics, and Gemini Therapeutics. In these positions, she had a depth of experience in therapeutic modalities, including biologics, small molecules, protein, antibodies, and oligonucleotides-based molecules (aptamer and siRNA), and in indications, including in the areas of ocular, hemophilia, cardiovascular, oncology, anti-inflammatory, metabolic, neurodegenerative, and rare diseases (transthyrethrin amyloidosis, and hyperoxarulia, hypercholerterolemia, and paroxysmal nocturnal hemoglobinuria, hemophilia a and b by insufficient thrombin generation due to deficiency in factor VIII or IX). She has more than 46 peer-reviewed publications, book chapters, and over 60 abstracts. Dr. Hutabarat received her Ph.D. from the University of Utah. She was awarded the Cystic Fibrosis Foundation postdoctoral fellowship to investigate PK and metabolism in cystic fibrosis patients at the University of Washington.